Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsten M Timms

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Breast Cancer Research and Treatment|May 27, 2015
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Virginia G Kaklamani, Jacqueline S Jeruss, Elisha Hughes, et al.
The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.
The Oncologist|March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and AssaysMark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Human Molecular Genetics|June 19, 2015
AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemiaElizabeth L Virts, Anna Jankowska, Craig Mackay, et al.
Breast Cancer Research and Treatment|August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesLauren Lenz, Chris Neff, Cara Solimeno, et al.
Journal of the National Cancer Institute|May 16, 2020
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-AnalysisRoshni D Kalachand, Britta Stordal, Stephen Madden, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Breast Cancer Research and Treatment|May 27, 2015
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Virginia G Kaklamani, Jacqueline S Jeruss, Elisha Hughes, et al.
The Lancet. Oncology|January 9, 2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trialEve Rodler, Priyanka Sharma, William E Barlow, et al.
The Oncologist|March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and AssaysMark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular CharacterizationStephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2016
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L Telli, Kirsten M Timms, Julia Reid, et al.
Human Molecular Genetics|June 19, 2015
AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemiaElizabeth L Virts, Anna Jankowska, Craig Mackay, et al.
Breast Cancer Research and Treatment|August 17, 2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypesLauren Lenz, Chris Neff, Cara Solimeno, et al.
Journal of the National Cancer Institute|May 16, 2020
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-AnalysisRoshni D Kalachand, Britta Stordal, Stephen Madden, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Pageof 4